FDA Approves JORNAY PM EXTENDED-RELEASE — Ironshore Pharmaceuticals Inc.

Ironshore Pharmaceuticals Inc. received FDA approval today for JORNAY PM Extended-Release capsules, providing a once-extended release treatment for ADHD to complement the company's existing morning branding. The market implications include potential patient and prescriber demand for the new formulation to fill gaps in bedtime management protocols. (Reference info: Brand: JORNAY PM EXTENDED-RELEASE Generic: METHYLPHENIDATE HYDROCHLORIDE Manufacturer: Ironshore Pharmaceuticals Inc. Route: ORAL App #: NDA209311 Date: 2018-08-08)